Skip to content

NBTX

Nanobiotix SA

NASDAQ · Healthcare · Biotechnology · FR

$21.08
−1.03%
Ask drillr

Year over year

Reported trailing growth

Revenue
-15.8%
EBITDA
+22.3%
EBIT
+32.7%
EPS
-0.9%
Free cash flow
-24.5%
Operating cash flow
-23.2%

Forward estimates

Based on analyst estimates

Revenue
+725.1%
EBITDA
+183.4%
EPS
+113.3%

Three-year CAGR

Revenue
+83.8%
EBITDA
+81.9%
EBIT
+84.2%
Net income
+64.8%
EPS
+65.3%
Free cash flow
-66.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026